S. 4152 · 117th Congress · Senate

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Active· Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced
May 5, 22
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Action Timeline

2
  1. MAY 05, 2022•IntroReferral

    Introduced in Senate

  2. MAY 05, 2022•IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

1

Health, Education, Labor, and Pensions Committee

sshr00

Referred: May 5, 2022

Active